SEC Comment Letter 0000000000-24-006844 to Inhibrx Biosciences, Inc. (INBX) (CIK 0002007919) (INBX)
Inhibrx Biosciences, Inc. (INBX) (CIK 0002007919)
Date: June 14, 2024 · CIK: 0002007919 · Accession: 0000000000-24-006844
AI Filing Summary & Sentiment
File numbers found in text: 333-280127
Letter
United States securities and exchange commission logo June 14, 2024 Mark Lappe Chief Executive Officer Inhibrx Biosciences, Inc. 11025 N. Torrey Pines Road, Suite 140 La Jolla, California 92037 Re:Inhibrx Biosciences, Inc. Registration Statement on Form S-1 Filed June 11, 2024 File No. 333-280127 Dear Mark Lappe: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Melanie Ruthrauff Levy
Show Raw Text
United States securities and exchange commission logo
June 14, 2024
Mark Lappe
Chief Executive Officer
Inhibrx Biosciences, Inc.
11025 N. Torrey Pines Road, Suite 140
La Jolla, California 92037
Re:Inhibrx Biosciences, Inc.
Registration Statement on Form S-1
Filed June 11, 2024
File No. 333-280127
Dear Mark Lappe:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Melanie Ruthrauff Levy